{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:19:55Z","timestamp":1785338395375,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1903125"],"award-info":[{"award-number":["U1903125"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","award":["82073799"],"award-info":[{"award-number":["82073799"]}],"id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","award":["21804144"],"award-info":[{"award-number":["21804144"]}],"id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","award":["U1903125"],"award-info":[{"award-number":["U1903125"]}],"id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","award":["20170030010004"],"award-info":[{"award-number":["20170030010004"]}],"id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2020JJ7061"],"award-info":[{"award-number":["2020JJ7061"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2020JJ5435"],"award-info":[{"award-number":["2020JJ5435"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jconrel.2021.08.035","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T10:31:10Z","timestamp":1629541870000},"page":"190-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myeloid leukemia"],"prefix":"10.1016","volume":"338","author":[{"given":"Shengmei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqi","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiming","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2021.08.035_bb0005","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.jconrel.2021.08.035_bb0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","article-title":"The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML","volume":"20","author":"Vetrie","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2021.08.035_bb0015","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2021.08.035_bb0020","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2021.08.035_bb0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrclinonc.2011.17","article-title":"Hematology: curing CML with imatinib--a dream come true?","volume":"8","author":"Deininger","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0030","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0035","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0040","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2021.08.035_bb0045","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0050","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019000760","article-title":"The simpler, the better: oral arsenic for acute promyelocytic leukemia","volume":"134","author":"Zhu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2021.08.035_bb0055","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1073\/pnas.0813280106","article-title":"Long-term efficacy and safety of all-trans retinoic acid\/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia","volume":"106","author":"Hu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0060","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2010-01-261040","article-title":"Autophagy contributes to therapy-induced degradation of the PML\/RARA oncoprotein","volume":"116","author":"Isakson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2021.08.035_bb0065","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/ncb1717","article-title":"Arsenic degrades PML or PML - RAR alpha through a SUMO-triggered RNF4\/ubiquitin-mediated pathway","volume":"10","author":"Lallemand-Breitenbach","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0070","doi-asserted-by":"crossref","first-page":"21683","DOI":"10.1073\/pnas.1016311108","article-title":"As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia","volume":"107","author":"Mao","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0075","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1182\/blood-2004-04-1433","article-title":"Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein","volume":"104","author":"Yin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2021.08.035_bb0080","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1073\/pnas.0813142106","article-title":"A systems biology understanding of the synergistic effects of arsenic sulfide and imatinib in BCR\/ABL-associated leukemia","volume":"106","author":"Zhang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0085","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3390\/toxins2061568","article-title":"Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview)","volume":"2","author":"Bal\u00e1\u017e","year":"2010","journal-title":"Toxins"},{"key":"10.1016\/j.jconrel.2021.08.035_bb0090","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.powtec.2011.04.027","article-title":"Properties of arsenic sulphide As4S4 nanoparticles prepared by high-energy milling","volume":"211","author":"Balaz","year":"2011","journal-title":"Powder Technol."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejps.2006.05.002","article-title":"Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding","volume":"29","author":"Wu","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0100","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s10853-014-8763-5","article-title":"Arsenic sulfide nanoparticles prepared by milling: properties, free-volume characterization, and anti-cancer effects","volume":"50","author":"Bujnakova","year":"2015","journal-title":"J. Mater. Sci."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0105","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1002\/anie.200900586","article-title":"Fluorescent nanogel of arsenic sulfide nanoclusters","volume":"48","author":"Wang","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0110","article-title":"Arsenic(II) sulfide quantum dots prepared by a wet process from its bulk","volume":"130","author":"Wang","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0115","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1016\/j.cclet.2020.05.027","article-title":"Cathepsin B-responsive nanodrug delivery systems for precise diagnosis and targeted therapy of malignant tumors","volume":"31","author":"Li","year":"2020","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0120","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1021\/acsnano.5b01320","article-title":"Clearance pathways and tumor targeting of imaging nanoparticles","volume":"9","author":"Yu","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2021.08.035_bb0125","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/nbt1340","article-title":"Renal clearance of quantum dots","volume":"25","author":"Choi","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jconrel.2011.09.069","article-title":"Impact of albumin on drug delivery - new applications on the horizon","volume":"157","author":"Elsadek","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.035_bb0135","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1021\/acs.chemrev.8b00733","article-title":"The role of ligands in the chemical synthesis and applications of inorganic nanoparticles","volume":"119","author":"Heuer-Jungemann","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0140","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2011.07.031","article-title":"Albumin-based nanoparticles as potential controlled release drug delivery systems","volume":"157","author":"Elzoghby","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.035_bb0145","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.cclet.2020.06.031","article-title":"Protein nanoparticles containing Cu(II) and DOX for efficient chemodynamic therapy via self-generation of H2O2","volume":"31","author":"Cao","year":"2020","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0150","doi-asserted-by":"crossref","first-page":"10845","DOI":"10.1002\/anie.201701366","article-title":"Smart human-serum-albumin-As2O3 nanodrug with self-amplified folate receptor-targeting ability for chronic myeloid leukemia treatment","volume":"56","author":"Peng","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0155","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.cclet.2020.02.036","article-title":"Advances in aggregatable nanoparticles for tumor-targeted drug delivery","volume":"31","author":"Yu","year":"2020","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0160","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cclet.2018.02.015","article-title":"One-pot photoreduction to prepare NIR-absorbing plasmonic gold nanoparticles tethered by amphiphilic polypeptide copolymer for synergistic photothermal-chemotherapy","volume":"30","author":"Yang","year":"2019","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0165","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.cclet.2020.04.035","article-title":"NIR-triggered drug delivery system based on phospholipid coated ordered mesoporous carbon for synergistic chemo-photothermal therapy of cancer cells","volume":"31","author":"Zhang","year":"2020","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.jconrel.2021.08.035_bb0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.scitotenv.2020.139229","article-title":"Graphene nanosheets damage the lysosomal and mitochondrial membranes and induce the apoptosis of RBL-2H3 cells","volume":"734","author":"Liu","year":"2020","journal-title":"Sci. Total Environ."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921004417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921004417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:40:03Z","timestamp":1777509603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365921004417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":34,"alternative-id":["S0168365921004417"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.08.035","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.08.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}